 |
|
|
|
 |
|
|
| Article 1 to 10 out of 20 concerning ThromboGenics NV
|
-
ThromboGenics and BioInvent announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibody
(06/19/2008)
ThromboGenics NV and BioInvent International AB announced that they have entered into a license agreement with Roche for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor ...
-
ThromboGenics Presents Further Results of the Vitreomacular Traction Trial (MIVI IIT)
(05/27/2008)
Results confirm the beneficial effects of microplasmin in patients with vitreomacular traction without need for vitrectomy throughout the 6 month follow-up period
ThromboGenics NV presented the six month follow up results from its Phase IIa MIVI IIT trial at the Euretina Congress in Vienna, Austria. The trial, which delivered positive clinical results in a number of the treated patients, was designed to ...
-
ThromboGenics Completes Patient Enrolment of MITI IV Trial, Evaluating the Safety and Preliminary Efficacy of Microplasmin
(04/11/2008)
ThromboGenics NV announced that it has completed patient enrolment for its Phase II MITI IV study. The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke ...
-
BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
(01/21/2008)
BioInvent International AB and co-development partner ThromboGenics NV announced that they have received approval from the regulatory authorities in Denmark to initiate a Phase I clinical trial of the novel anti-cancer agent TB-403. TB-403 is a ...
-
ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
(11/15/2007)
ThromboGenics NV announced that it will progress with the development of its novel anti-VPAC* antibody for the treatment of thrombocytopenia, including chemotherapy-induced thrombocytopenia.Thrombocytopenia, which is the reduced number of platelets ...
-
ThromboGenics and BioInvent Publicate Data on a Novel Class of Angiogenesis Inhibitors
(11/05/2007)
Novel anti-PlGF antibody, TB-403, being developed by ThromboGenics and BioInvent for
ThromboGenics NV and co-development partner, BioInvent International, announced the publication of data that highlight for the first time the therapeutic potential of anti-PlGF agents to treat cancer based on research performed at the University of ...
-
On the road to a new cancer therapy starving the tumor
(11/02/2007)
Cancer is the major cause of death among men. Based on the current trends, scientists predict that, by about 2010, cancer will be the No. 1 cause of death for women as well. VIB scientists connected to the Katholieke Universiteit Leuven, in ...
-
ThromboGenics and Rhein Minapharm Announce Agreement for Next-Generation Thrombolytic Agent
(10/16/2007)
Agreement Covers Development and Commercialization of Novel Heart Attack Treatment in Middle East and Africa
ThromboGenics NV and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE jointly announced that they have completed a license agreement for the production, clinical development and commercialization of ThromboGenics' THR-174, the ...
-
ThromboGenics Completes Enrolment of Patients for the Vitreomacular Traction Trial (MIVI IIT)
(09/25/2007)
ThromboGenics NV announces that it has completed patient enrolment for the Phase IIa MIVI IIT trial evaluating the safety and efficacy of microplasmin for the treatment of vitreomacular traction, including macular holes.Vitreomacular traction is a ...
-
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
(09/10/2007)
Decision taken to advance novel, long-acting anticoagulant into Phase II clinical development
BioInvent International AB and co-development partner ThromboGenics NV announced that they have successfully completed enrollment and initial follow-up of all volunteers in the first Phase I trial of TB-402, which is being developed for the ...
Additional information
ThromboGenics NV
Leuven, Belgium
Company
|
|
|
|
|
|
Top
